Related Experiment Video
Updated: Jan 3, 2026
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
An artificial nucleoside that simultaneously detects and combats drug resistance to doxorubicin
Jung-Suk Choi1, Anthony Berdis1,2
1Department of Chemistry, Cleveland State University, Cleveland, OH.
Objectives:
Doxorubicin is a DNA-damaging agent used to treat hematological cancers. Unfortunately, drug resistance can occur by defective DNA repair activity coupled with the ability of DNA polymerases to misreplicate unrepaired DNA lesions. This study demonstrates that the efficacy of doxorubicin can be improved by using an artificial nucleoside to efficiently and selectively inhibit this activity.
Methods:
In vitro studies using acute lymphoblastic leukemia cell lines define the mechanism of cell death caused by combining an artificial nucleoside with doxorubicin.
Results:
Flow cytometry experiments demonstrate that combining an artificial nucleoside with doxorubicin potentiates the cell killing effects of the drug by increasing apoptosis. The potentiation effect correlates with expression of TdT, a specialized DNA polymerase overexpressed in acute lymphoblastic leukemia. Cell cycle experiments demonstrate that this combination blocks cells at S-phase prior to inducing apoptosis. Finally, the unique chemical composition of the nucleoside analog was used to visualize the replication of damaged DNA in TdT-positive cells. This represents a potential diagnostic tool to easily identify doxorubicin-resistant cancer cells.
Conclusion:
Studies demonstrate that a novel artificial nucleoside improves the therapeutic efficacy of doxorubicin, thereby reducing the risk of potential side effects caused by the DNA-damaging agent.
Insights
A novel artificial nucleoside enhances doxorubicin chemotherapy for hematological cancers by inhibiting DNA repair and misreplication, increasing cancer cell death and potentially serving as a diagnostic marker.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Doxorubicin is a key chemotherapy agent for hematological cancers.
- Drug resistance arises from defective DNA repair and DNA polymerase misreplication of lesions.
- Targeting these resistance mechanisms can improve treatment efficacy.
Purpose of the Study:
- To investigate the efficacy of a novel artificial nucleoside in combination with doxorubicin.
- To elucidate the mechanism of cell death induced by this combination therapy.
- To explore the potential of the nucleoside analog as a diagnostic tool.
Main Methods:
- In vitro studies using acute lymphoblastic leukemia cell lines.
- Flow cytometry to assess apoptosis and cell cycle progression.
- Utilizing the nucleoside analog's unique chemical properties for visualization.
Main Results:
- The artificial nucleoside potentiates doxorubicin's cancer cell killing effects by increasing apoptosis.
- This potentiation correlates with TdT expression, a marker in acute lymphoblastic leukemia.
- The combination therapy causes S-phase arrest before inducing apoptosis.
- The nucleoside analog enabled visualization of DNA replication in TdT-positive cells, suggesting diagnostic utility.
Conclusions:
- A novel artificial nucleoside significantly improves doxorubicin's therapeutic efficacy.
- This approach reduces the risk of side effects associated with DNA-damaging agents.
- The findings suggest a new strategy for overcoming chemotherapy resistance and a potential diagnostic method.
More Related Videos
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
